HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials by Gennari Alessandra, Sormani Maria Pia, Pronzato Paolo, Puntoni Matteo, Colozza Mariantonietta, Pfeffer Ulrich, Bruzzi Paolo in Journal of the National Cancer Institute (2008). PubMed

Abstract

Adjuvant chemotherapy with anthracyclines improves disease-free and overall survival compared with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer. The role of HER2 status as a marker of anthracycline responsiveness has been explored by subset analyses within randomized clinical trials, with inconsistent results. We performed a pooled analysis of the interaction between HER2 status and the efficacy of adjuvant anthracyclines based on the published subset data.

[ hide abstract ]

Discussed In Paper